JP2020517640A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020517640A5 JP2020517640A5 JP2019556889A JP2019556889A JP2020517640A5 JP 2020517640 A5 JP2020517640 A5 JP 2020517640A5 JP 2019556889 A JP2019556889 A JP 2019556889A JP 2019556889 A JP2019556889 A JP 2019556889A JP 2020517640 A5 JP2020517640 A5 JP 2020517640A5
- Authority
- JP
- Japan
- Prior art keywords
- agent
- adc
- cancer
- individual
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 CC(C1)CC=C(C2)[C@]1C(C)C(*)c(c(*)c(CC*c(c(*)c1N(*)C(C3N4C=C(*)C3)*=*)c(*)c(*)c1C4=O)c(*)c1*)c1C2=O Chemical compound CC(C1)CC=C(C2)[C@]1C(C)C(*)c(c(*)c(CC*c(c(*)c1N(*)C(C3N4C=C(*)C3)*=*)c(*)c(*)c1C4=O)c(*)c1*)c1C2=O 0.000 description 1
- SDUQYLNIPVEERB-ZJXFTUPMSA-N NC(C=CN1[C@@H](C2(F)F)O[C@H](CO)C2O)=NC1=O Chemical compound NC(C=CN1[C@@H](C2(F)F)O[C@H](CO)C2O)=NC1=O SDUQYLNIPVEERB-ZJXFTUPMSA-N 0.000 description 1
Applications Claiming Priority (21)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1706256.3 | 2017-04-20 | ||
| GBGB1706258.9A GB201706258D0 (en) | 2017-04-20 | 2017-04-20 | Combination therapy |
| GB1706253.0 | 2017-04-20 | ||
| GBGB1706259.7A GB201706259D0 (en) | 2017-04-20 | 2017-04-20 | Combination therapy |
| GBGB1706261.3A GB201706261D0 (en) | 2017-04-20 | 2017-04-20 | Combination therapy |
| GB1706254.8 | 2017-04-20 | ||
| GBGB1706257.1A GB201706257D0 (en) | 2017-04-20 | 2017-04-20 | Combination therapy |
| GB1706260.5 | 2017-04-20 | ||
| GBGB1706260.5A GB201706260D0 (en) | 2017-04-20 | 2017-04-20 | Combination therapy |
| GB1706257.1 | 2017-04-20 | ||
| GBGB1706253.0A GB201706253D0 (en) | 2017-04-20 | 2017-04-20 | Combination therapy |
| GB1706261.3 | 2017-04-20 | ||
| GBGB1706254.8A GB201706254D0 (en) | 2017-04-20 | 2017-04-20 | Combination therapy |
| GBGB1706256.3A GB201706256D0 (en) | 2017-04-20 | 2017-04-20 | Combination therapy |
| GB1706259.7 | 2017-04-20 | ||
| GB1706258.9 | 2017-04-20 | ||
| GBGB1802947.0A GB201802947D0 (en) | 2018-02-23 | 2018-02-23 | Combination therapy |
| GB1802947.0 | 2018-02-23 | ||
| GBGB1805660.6A GB201805660D0 (en) | 2018-04-05 | 2018-04-05 | Combination Therapy |
| GB1805660.6 | 2018-04-05 | ||
| PCT/EP2018/060215 WO2018193105A1 (en) | 2017-04-20 | 2018-04-20 | Combination therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020517640A JP2020517640A (ja) | 2020-06-18 |
| JP2020517640A5 true JP2020517640A5 (enExample) | 2021-08-12 |
Family
ID=62111031
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019556889A Pending JP2020517640A (ja) | 2017-04-20 | 2018-04-20 | 併用療法 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20200405879A1 (enExample) |
| EP (1) | EP3612839A1 (enExample) |
| JP (1) | JP2020517640A (enExample) |
| KR (1) | KR20190137151A (enExample) |
| CN (2) | CN110869765A (enExample) |
| AU (1) | AU2018253951A1 (enExample) |
| BR (1) | BR112019021822A2 (enExample) |
| CA (1) | CA3057749A1 (enExample) |
| MX (1) | MX2019012462A (enExample) |
| WO (1) | WO2018193105A1 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2989106T3 (pl) | 2013-04-25 | 2017-08-31 | Beigene, Ltd. | Połączone związki heterocykliczne jako inhibitory kinazy białkowej |
| SMT202300039T1 (it) | 2013-09-13 | 2023-03-17 | Beigene Switzerland Gmbh | Anticorpi anti-pd1 e loro uso come terapia e per diagnostica |
| TWI726608B (zh) | 2014-07-03 | 2021-05-01 | 英屬開曼群島商百濟神州有限公司 | 抗pd-l1抗體及其作為治療及診斷之用途 |
| WO2018007885A1 (en) | 2016-07-05 | 2018-01-11 | Beigene, Ltd. | COMBINATION OF A PD-l ANTAGONIST AND A RAF INHIBITOR FOR TREATING CANCER |
| IL293319B1 (en) | 2016-08-16 | 2026-01-01 | Beone Medicines Ltd | Crystal structure of s)–7–(1–acryloylpiperidin–4–yl)–2–(4–)phenoxyphenyl)–4,5,6,7–tetra–hydropyrazolo(1,5–a)pyrimidine–3–carboxamide, methods of preparation and uses thereof |
| CN110087680B (zh) * | 2016-08-19 | 2024-03-19 | 百济神州有限公司 | 使用包含btk抑制剂的组合产品治疗癌症 |
| EP3573989A4 (en) | 2017-01-25 | 2020-11-18 | Beigene, Ltd. | CRYSTALLINE FORMS OF (S) -7- (1- (BUT-2-YNOYL) PIPERIDIN-4-YL) -2- (4-PHENOXYPHENYL) -4, 5, 6, 7-TETRAHY DROPYRAZOLO [1, 5-A ] PYRIMIDINE-3-CARBOXAMIDE, PREPARATION AND ASSOCIATED USES |
| MX2020010523A (es) | 2017-02-27 | 2021-02-09 | Third Pole Inc | Sistemas y metodos para generar oxido nitrico. |
| EP3645569A4 (en) | 2017-06-26 | 2021-03-24 | BeiGene, Ltd. | IMMUNOTHERAPY FOR LIVER CELL CARCINOMA |
| WO2019034009A1 (en) | 2017-08-12 | 2019-02-21 | Beigene, Ltd. | BTK INHIBITOR WITH ENHANCED DOUBLE SELECTIVITY |
| US11786529B2 (en) | 2017-11-29 | 2023-10-17 | Beigene Switzerland Gmbh | Treatment of indolent or aggressive B-cell lymphomas using a combination comprising BTK inhibitors |
| CA3107085A1 (en) * | 2018-08-31 | 2020-03-05 | Adc Therapeutics Sa | Combination of anti-cd19 antibody-pyrroloenzodiazepine conjugate and ve netoclax |
| WO2020109251A1 (en) * | 2018-11-29 | 2020-06-04 | Adc Therapeutics Sa | Dosage regime |
| US20220117938A1 (en) * | 2019-01-18 | 2022-04-21 | Dracen Pharmaceuticals, Inc. | Combinaton therapy with a don prodrug and an immune checkpoint inhibitor |
| WO2020232414A1 (en) | 2019-05-15 | 2020-11-19 | Third Pole, Inc. | Architectures for production of nitric oxide |
| CN110128551A (zh) * | 2019-06-05 | 2019-08-16 | 上海科弈药业科技有限公司 | 一种针对cd19+肿瘤的多功能融合蛋白及其应用 |
| GB201908128D0 (en) * | 2019-06-07 | 2019-07-24 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
| EP3981399A4 (en) | 2019-06-10 | 2023-05-31 | BeiGene Switzerland GmbH | ORAL SOLID TABLET WITH A TYROSINE KINAS INHIBITOR AND METHOD OF MANUFACTURE THEREOF |
| SG11202113092WA (en) * | 2019-06-10 | 2021-12-30 | Adc Therapeutics Sa | Combination therapy comprising an anti-cd19 antibody drug conjugate and a pi3k inhibitor or a secondary agent |
| US12599603B2 (en) | 2019-09-03 | 2026-04-14 | Intra-Cellular Therapies, Inc. | Methods of treatment |
| EP4069069A4 (en) | 2020-01-11 | 2024-07-03 | Third Pole, Inc. | SYSTEMS AND METHODS FOR NITROGEN OXIDE PRODUCTION WITH HUMIDITY CONTROL |
| EP4167920A4 (en) | 2020-06-18 | 2024-06-12 | Third Pole, Inc. | Systems and methods for preventing and treating infections with nitric oxide |
| GB202011993D0 (en) | 2020-07-31 | 2020-09-16 | Adc Therapeutics Sa | ANTI-IL 13Ra2 antibodies |
| WO2022082072A1 (en) | 2020-10-16 | 2022-04-21 | Third Pole, Inc. | Nitric oxide generation process controls |
| CN117120474A (zh) * | 2021-04-14 | 2023-11-24 | 吉利德科学公司 | 用于治疗癌症的对CD47/SIRPα结合和NEDD8活化酶E1调节亚基的共同抑制 |
| WO2022228706A1 (en) * | 2021-04-30 | 2022-11-03 | F. Hoffmann-La Roche Ag | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibody |
| KR20240028449A (ko) | 2021-06-29 | 2024-03-05 | 에이디씨 테라퓨틱스 에스에이 | 항체-약물 접합체를 이용한 병용 요법 |
| WO2023049873A1 (en) | 2021-09-23 | 2023-03-30 | Third Pole, Inc. | Systems and methods for delivering nitric oxide |
| US12569628B2 (en) | 2022-04-14 | 2026-03-10 | Third Pole, Inc. | Delivery of medicinal gas in a liquid medium |
| US11786531B1 (en) | 2022-06-08 | 2023-10-17 | Beigene Switzerland Gmbh | Methods of treating B-cell proliferative disorder |
| EP4410314A1 (en) * | 2023-02-02 | 2024-08-07 | ADC Therapeutics SA | Combination therapy comprising anti-cd22 antibody-drug conjugate and irak1 inhibitor |
| WO2025249980A1 (ko) * | 2024-05-31 | 2025-12-04 | (주)노보메디슨 | 림프종의 예방 또는 치료를 위한 포셀티닙의 병용투여 요법 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2524929A1 (en) * | 2011-05-17 | 2012-11-21 | Sanofi | Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms |
| EP2550975A1 (en) * | 2011-07-29 | 2013-01-30 | Sanofi | Combination therapy for the treatment of CD19+ B-cell malignancies symptoms comprising an anti-CD19 maytansinoid immunoconjugate and rituximab |
| DK2839860T3 (da) * | 2012-10-12 | 2019-06-17 | Medimmune Ltd | Pyrrolobenzodiazepiner og konjugater deraf |
| DK2906298T3 (en) * | 2012-10-12 | 2018-12-17 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
| ES2693370T3 (es) * | 2013-05-02 | 2018-12-11 | F. Hoffmann-La Roche Ag | Politerapia de un anticuerpo CD20 afucosilado con un conjugado de anticuerpo CD22-fármaco |
| WO2015052534A1 (en) * | 2013-10-11 | 2015-04-16 | Spirogen Sàrl | Pyrrolobenzodiazepine-antibody conjugates |
| GB201506399D0 (en) * | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
-
2018
- 2018-04-20 EP EP18721976.1A patent/EP3612839A1/en not_active Withdrawn
- 2018-04-20 BR BR112019021822-0A patent/BR112019021822A2/pt not_active IP Right Cessation
- 2018-04-20 JP JP2019556889A patent/JP2020517640A/ja active Pending
- 2018-04-20 WO PCT/EP2018/060215 patent/WO2018193105A1/en not_active Ceased
- 2018-04-20 AU AU2018253951A patent/AU2018253951A1/en not_active Abandoned
- 2018-04-20 CN CN201880038974.5A patent/CN110869765A/zh active Pending
- 2018-04-20 MX MX2019012462A patent/MX2019012462A/es unknown
- 2018-04-20 KR KR1020197033821A patent/KR20190137151A/ko not_active Ceased
- 2018-04-20 CA CA3057749A patent/CA3057749A1/en active Pending
- 2018-04-20 CN CN202610843686.3A patent/CN122461487A/zh active Pending
- 2018-04-20 US US16/605,701 patent/US20200405879A1/en not_active Abandoned
-
2022
- 2022-08-11 US US17/819,185 patent/US20230149556A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230149556A1 (en) | Combination therapy | |
| JP7402691B2 (ja) | 抗ｃｄ２５抗体薬物複合体による併用療法 | |
| JP6591428B2 (ja) | 癌治療のためのｐｄ−１拮抗薬およびｖｅｇｆｒ阻害剤の組み合わせ | |
| JP2020517629A5 (enExample) | ||
| WO2016200836A1 (en) | Methods of treating cancer using anti-ox40 antibodies | |
| EP3303397A1 (en) | Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists | |
| US20200129638A1 (en) | Combination therapy with an anti-psma antibody-drug conjugate | |
| JP2020517652A5 (enExample) | ||
| KR20210006405A (ko) | 암의 치료를 위한 PD-1/PD-L1, TGFβ 및 DNA-PK의 조합 억제 | |
| KR20190135028A (ko) | 암의 치료를 위한 항-pd-l1 항체 및 dna-pk 억제제의 병용 | |
| JP7740994B2 (ja) | 抗ｃｄ１９抗体薬物複合体とｐｉ３ｋ阻害剤又は二次薬剤を含む併用治療 | |
| KR20250052418A (ko) | 항-ccr8 항체 및 그의 용도 | |
| JP7590083B2 (ja) | 併用療法 | |
| KR20220095205A (ko) | 암의 치료를 위한 방사선요법과 PD-1, TGFβ 및 ATM의 조합 억제 | |
| JP2021533090A (ja) | 併用療法 | |
| EA046551B1 (ru) | Комбинированная терапия |